Blood: Risk of bleeding in acquired haemophilia A (AHA) and response to hemostatic treatment

Acquired haemophilia A (AHA) is caused by autoantibodies of anticoagulant VIII (FVIII), usually accompanied by accidental bleedingCompared to congenital haemophilia, residual FVIII activity in patients appears to be unrelated to the risk of bleeding indicated by previous studiesRisk factors forbleeding have not been describedThe researchers used data from the prospective GTH-AH study to assess the risk of bleeding and the effectiveness of hemostatic therapyThe activity of FVIII is detected at the baseline and in the week thereafterThe treatment physician evaluates the bleeding event102 patients with 289 haemorrhage events recordedFifty-nine percent of patients had 141 new blood transfusions from day one, with an average bleeding rate of 0.13 times/patient/week in 1-12 weeks and an average bleeding rate of 0.27 times/patient/week before partial remissionthe weekly detection of FVIII activity was significantly related to bleeding rate, but only by reaching FVIII?50% to eliminate the risk of bleedingGood WHO performance (score 0 or higher) assessed at baseline was associated with a lower bleeding rateHemorrhage therapy is reported to be effective for 96% of bleedingin general, the risk of new bleeding after the first diagnosis of AHA remains high until partial relief, and weekly testing of FVIII activity may help to assess individual risk of bleedingThe results of this study will help to determine future treatment strategies for preventing bleeding in Patients with AHA